[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity
David Young, President of Research & Development and a director at Processa Pharmaceuticals, Inc. (PCSA), reported equity awards granted on 10/01/2025. The filing shows 111,000 Restricted Stock Units granted, each converting to one share upon vesting: one-third vests on 10/01/2026 and the remainder vests monthly over two years until 10/01/2028. It also reports 333,000 stock options with an exercise price of $0.198; those options vest one-third on the first anniversary of the grant and the remainder ratably over the next two years. Following the transactions the reporting person beneficially owns the awarded 111,000 RSUs and 333,000 options. The Form is signed by an attorney-in-fact on 10/03/2025.
David Young, Presidente di Ricerca e Sviluppo e direttore presso Processa Pharmaceuticals, Inc. (PCSA), ha riferito premi in equity concessi il 10/01/2025. La pratica mostra 111.000 Restricted Stock Units (RSU) assegnate, ciascuna convertibile in una azione al vesting: un terzo matura il 10/01/2026 e il resto matura mensilmente nell’arco di due anni fino al 10/01/2028. Riporta inoltre 333.000 stock options con prezzo di esercizio di $0,198; tali opzioni maturano un terzo al primo anniversario della concessione e il resto in modo proporzionale nei due anni successivi. Dopo le transazioni la persona che segnala possiede in modo utile le RSU assegnate 111.000 e le 333.000 opzioni. Il modulo è firmato da un procuratore-in-fatto il 10/03/2025.
David Young, Presidente de Investigación y Desarrollo y director de Processa Pharmaceuticals, Inc. (PCSA), reportó premios en acciones concedidos el 10/01/2025. El registro muestra 111.000 Restricted Stock Units (RSU) otorgadas, cada una convirtiéndose en una acción al vesting: un tercio vence el 10/01/2026 y el resto vence mensualmente durante dos años hasta el 10/01/2028. También reporta 333.000 stock options con un precio de ejercicio de $0,198; esas opciones vencen un tercio al primer aniversario de la concesión y el resto de forma proporcionada durante los dos años siguientes. Tras las transacciones, la persona reportante posee beneficialmente las RSU otorgadas 111.000 y 333.000 opciones. El Formulario está firmado por un apoderado en 10/03/2025.
David Young, 연구개발(R&D) 책임자이자 Processa Pharmaceuticals, Inc. (PCSA)의 이사인 그는 2025년 10월 1일에 부여된 주식 보상에 대해 보고했습니다. 공시에는 각각 vesting 시 한 주식으로 전환되는 111,000 Restricted Stock Units가 있으며, 그 중 2026년 10월 1일에 3분의 1이 vest하고 나머지는 2년 동안 매월 vesting됩니다. 또한 행사 가격이 $0.198인 333,000 stock options가 보고되며, 해당 옵션은 부여의 첫 해에 3분의 1이 vest하고 나머지는 다음 2년에 걸쳐 비례 vest 됩니다. 거래 후 보고자는 111,000 RSU와 333,000 옵션을 실질적으로 소유하게 됩니다. 양식은 2025년 10월 3일에 대리인에 의해 서명되었습니다.
David Young, Président de la Recherche et Développement et directeur de Processa Pharmaceuticals, Inc. (PCSA), a rapporté des attributions d’actions accordées le 01/10/2025. Le dossier indique 111.000 Restricted Stock Units (RSU) accordées, chacune se convertissant en une action lors du vesting : un tiers vest le 01/10/2026 et le reste vest progressivement sur deux ans jusqu’au 01/10/2028. Il est également indiqué 333.000 stock options avec un prix d’exercice de $0,198; ces options vestent un tiers au premier anniversaire de la concession et le reste de manière proportionnelle au cours des deux années suivantes. Après les transactions, la personne déclarante détient de manière bénéficiaire les RSU attribuées 111.000 et les 333.000 options. Le formulaire est signé par un mandataire le 03/10/2025.
David Young, Präsident für Forschung & Entwicklung und Vorstand bei Processa Pharmaceuticals, Inc. (PCSA), berichtete über Aktienzuwendungen, die am 10/01/2025 gewährt wurden. Die Einreichung zeigt 111.000 Restricted Stock Units (RSU), von denen jede beim Vesting in eine Aktie umgewandelt wird: Ein Drittel vestet am 10/01/2026 und der Rest vestet monatlich über zwei Jahre bis zum 10/01/2028. Es werden auch 333.000 stock options mit einem Ausübungspreis von $0,198 berichtet; diese Optionen vesten ein Drittel am ersten Jahrestag der Gewährung und der Rest proportional über die nächsten zwei Jahre. Nach den Transaktionen besitzt die meldende Person vorteilhaft die zugewiesenen 111.000 RSUs und 333.000 Optionen. Das Formular ist am 03/10/2025 von einem Bevollmächtigten unterzeichnet.
David Young, رئيس قسم البحث والتطوير وعضو مجلس إدارة في Processa Pharmaceuticals, Inc. (PCSA)، أبلغ عن منح أسهم تعويضية بتاريخ 10/01/2025. يبيّن الملف وجود 111,000 وحدات أسهم مقيدة (RSU)، كل منها تتحول إلى سهم واحد عند الاستحقاق: ثلثها يستحق في 10/01/2026 والباقي يستحق شهرياً على مدى سنين حتى 10/01/2028. كما يذكر 333,000 خيار أسهم بسعر ممارسة $0.198؛ تستحق تلك الخيارات ثلثاً عند السنة الأولى من المنحة وباقيها بالتناسب على مدار العامين التاليين. بعد المعاملات، يمتلك الشخص المُبلغ عنه بشكل مستفيد الـ111,000 RSU و333,000 خيار أسهم. النموذج موقع من وصي في 10/03/2025.
David Young，负责研究与开发的总裁及 Processa Pharmaceuticals, Inc. (PCSA) 的董事，报告了在 2025/10/01 授予的股权奖励。备案显示 111,000 个受限股票单位（RSU），每单位在归属时可转为一股股票：其中三分之一在 2026/10/01 到期归属，其余在未来两年内按月归属至 2028/10/01。还报告了 333,000 股权期权，行权价为 $0.198；这些期权在授予后的第一周年归属三分之一，其余在接下来的两年内按比例归属。交易完成后，申报人实益拥有被授予的 111,000RSU 和 333,000 期权。该表格由一名代理人于 2025/10/03 签署。
- 111,000 Restricted Stock Units awarded with clear time‑based vesting through 10/01/2028
- 333,000 stock options granted with a defined $0.198 exercise price and three‑year vesting schedule
- Timely Section 16 disclosure filed (transaction 10/01/2025; Form signed 10/03/2025)
- Potential future dilution from up to 444,000 shares subject to vesting/exercise
- No performance conditions disclosed; awards are solely time‑vested which may not directly tie pay to milestones
Insights
Equity grants align executive pay with shareholder outcomes while creating potential future share issuance.
The report documents grants totaling 444,000 equity instruments: 111,000 RSUs and 333,000 options awarded on 10/01/2025. RSU vesting is time‑based through 10/01/2028, and options vest over three years with an $0.198 exercise price. These structures are typical for retention and long‑term incentive design and tie a senior R&D officer’s compensation to future equity performance.
This matters because these awards will only convert into actual shares upon vesting/exercise, which creates potential dilution and aligns the reporting person’s interests with long‑term shareholder value; the filing shows the specific vesting schedule and exercise price.
Disclosure follows Section 16 reporting rules and confirms insider status and timing of the grant.
The Form 4 identifies David Young as both a director and an officer and records the transactions as individual filings. The Form indicates the transactions occurred on 10/01/2025 and were reported by 10/03/2025, consistent with prompt reporting requirements. The signature by an attorney‑in‑fact is included.
This is relevant to investors monitoring insider activity because it provides transparent timing, award size, and vesting details as required by law.
David Young, Presidente di Ricerca e Sviluppo e direttore presso Processa Pharmaceuticals, Inc. (PCSA), ha riferito premi in equity concessi il 10/01/2025. La pratica mostra 111.000 Restricted Stock Units (RSU) assegnate, ciascuna convertibile in una azione al vesting: un terzo matura il 10/01/2026 e il resto matura mensilmente nell’arco di due anni fino al 10/01/2028. Riporta inoltre 333.000 stock options con prezzo di esercizio di $0,198; tali opzioni maturano un terzo al primo anniversario della concessione e il resto in modo proporzionale nei due anni successivi. Dopo le transazioni la persona che segnala possiede in modo utile le RSU assegnate 111.000 e le 333.000 opzioni. Il modulo è firmato da un procuratore-in-fatto il 10/03/2025.
David Young, Presidente de Investigación y Desarrollo y director de Processa Pharmaceuticals, Inc. (PCSA), reportó premios en acciones concedidos el 10/01/2025. El registro muestra 111.000 Restricted Stock Units (RSU) otorgadas, cada una convirtiéndose en una acción al vesting: un tercio vence el 10/01/2026 y el resto vence mensualmente durante dos años hasta el 10/01/2028. También reporta 333.000 stock options con un precio de ejercicio de $0,198; esas opciones vencen un tercio al primer aniversario de la concesión y el resto de forma proporcionada durante los dos años siguientes. Tras las transacciones, la persona reportante posee beneficialmente las RSU otorgadas 111.000 y 333.000 opciones. El Formulario está firmado por un apoderado en 10/03/2025.
David Young, 연구개발(R&D) 책임자이자 Processa Pharmaceuticals, Inc. (PCSA)의 이사인 그는 2025년 10월 1일에 부여된 주식 보상에 대해 보고했습니다. 공시에는 각각 vesting 시 한 주식으로 전환되는 111,000 Restricted Stock Units가 있으며, 그 중 2026년 10월 1일에 3분의 1이 vest하고 나머지는 2년 동안 매월 vesting됩니다. 또한 행사 가격이 $0.198인 333,000 stock options가 보고되며, 해당 옵션은 부여의 첫 해에 3분의 1이 vest하고 나머지는 다음 2년에 걸쳐 비례 vest 됩니다. 거래 후 보고자는 111,000 RSU와 333,000 옵션을 실질적으로 소유하게 됩니다. 양식은 2025년 10월 3일에 대리인에 의해 서명되었습니다.
David Young, Président de la Recherche et Développement et directeur de Processa Pharmaceuticals, Inc. (PCSA), a rapporté des attributions d’actions accordées le 01/10/2025. Le dossier indique 111.000 Restricted Stock Units (RSU) accordées, chacune se convertissant en une action lors du vesting : un tiers vest le 01/10/2026 et le reste vest progressivement sur deux ans jusqu’au 01/10/2028. Il est également indiqué 333.000 stock options avec un prix d’exercice de $0,198; ces options vestent un tiers au premier anniversaire de la concession et le reste de manière proportionnelle au cours des deux années suivantes. Après les transactions, la personne déclarante détient de manière bénéficiaire les RSU attribuées 111.000 et les 333.000 options. Le formulaire est signé par un mandataire le 03/10/2025.
David Young, Präsident für Forschung & Entwicklung und Vorstand bei Processa Pharmaceuticals, Inc. (PCSA), berichtete über Aktienzuwendungen, die am 10/01/2025 gewährt wurden. Die Einreichung zeigt 111.000 Restricted Stock Units (RSU), von denen jede beim Vesting in eine Aktie umgewandelt wird: Ein Drittel vestet am 10/01/2026 und der Rest vestet monatlich über zwei Jahre bis zum 10/01/2028. Es werden auch 333.000 stock options mit einem Ausübungspreis von $0,198 berichtet; diese Optionen vesten ein Drittel am ersten Jahrestag der Gewährung und der Rest proportional über die nächsten zwei Jahre. Nach den Transaktionen besitzt die meldende Person vorteilhaft die zugewiesenen 111.000 RSUs und 333.000 Optionen. Das Formular ist am 03/10/2025 von einem Bevollmächtigten unterzeichnet.
FAQ
What did Processa (PCSA) insider David Young receive on 10/01/2025?
When do the RSUs and options vest?
What is the exercise price of the options granted to David Young?
Does the Form 4 show beneficial ownership after the grant?
Who filed and signed the Form 4?
